{
    "Trade/Device Name(s)": [
        "AMDL-ELISA DR-70\u00ae (FDP)"
    ],
    "Submitter Information": "AMDL Inc.",
    "510(k) Number": "K072901",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NTY"
    ],
    "Summary Letter Date": "July 1, 2008",
    "Summary Letter Received Date": "May 13, 2008",
    "Submission Date": "May 12, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Fibrin/Fibrinogen Degradation Products (FDP)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microtiter plate reader (450 nm)",
        "ELISA plate (96-well format)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Immunoassay"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Calibrator",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for AMDL-ELISA DR-70\u00ae (FDP) immunoassay for quantitative measurement of FDP in serum to monitor colorectal cancer progression",
    "Indications for Use Summary": "Aid in monitoring disease progression in patients previously diagnosed with colorectal cancer by serial quantitative measurement of FDP in human serum, used alongside other standard clinical modalities",
    "fda_folder": "Immunology"
}